Literature DB >> 15834246

Detection of 677CT/1298AC "double variant" chromosomes: implications for interpretation of MTHFR genotyping results.

Nicholas M Brown1, Victoria M Pratt, Arlene Buller, Lisa Pike-Buchanan, Joy B Redman, Weimin Sun, Rebecca Chen, Beryl Crossley, Matthew J McGinniss, Franklin Quan, Charles M Strom.   

Abstract

PURPOSE: Genotyping 37,026 individuals as part of a thrombophilia evaluation, we determined and analyzed the genotypic frequencies of the 677CT and 1298AC mutations in the methylenetetrahydrofolate reductase (MTHFR) gene.
METHODS: The 677CT and 1298AC mutations in the MTHFR gene were determined by either a laboratory-developed test involving PCR amplification and restriction digestion utilizing the ABI 3100 capillary electrophoresis apparatus (Applied Biosystems Inc) or by using an Analyte Specific Reagent (ASR) supplied by Third Wave Technologies. The genotype for three specimens with triple variant MTHFR mutations were confirmed by DNA sequencing on the ABI 3100 capillary electrophoresis apparatus.
RESULTS: The MTHFR frequencies of the 677CT/1298AA, 677CC/1298AC, 677CT/1298AC, 677CC/1298AA, 677TT/1298AA, 677CC/1298CC, 677TT/1298AC, and 677CT/1298CC genotypes were 0.228, 0.208, 0.198, 0.153, 0.122, 0.088, 0.0005, and 0.0003, respectively.
CONCLUSIONS: Individuals containing double variant MTHFR mutations on one allele (cis) cannot be distinguished between compound heterozygotes (trans) for 677CT and 1298AC mutations in routine clinical testing, a genotype associated with thrombophilia. Such patients could be inappropriately counseled for being at high risk for thrombotic episodes. Until information regarding prevalence and the clinical consequences of this double variant (cis) allele becomes available, caution should be used in interpreting the genotyping results of compound heterozygosity for 677CT and 1298AC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834246     DOI: 10.1097/01.gim.0000159904.92850.d5

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  6 in total

1.  Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.

Authors:  Shannon D Barker; Sherri Bale; Jessica Booker; Arlene Buller; Soma Das; Kenneth Friedman; Andrew K Godwin; Wayne W Grody; Edward Highsmith; Jeffery A Kant; Elaine Lyon; Rong Mao; Kristin G Monaghan; Deborah A Payne; Victoria M Pratt; Iris Schrijver; Antony E Shrimpton; Elaine Spector; Milhan Telatar; Lorraine Toji; Karen Weck; Barbara Zehnbauer; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2009-09-18       Impact factor: 5.568

2.  Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology.

Authors:  Marelize Swart; Wesley M Stansberry; Victoria M Pratt; Elizabeth B Medeiros; Patrick J Kiel; Fei Shen; Bryan P Schneider; Todd C Skaar
Journal:  J Mol Diagn       Date:  2019-02-20       Impact factor: 5.568

3.  Report of Confirmation of the rs7853758 and rs885004 Haplotype in SLC28A3.

Authors:  Wesley M Stansberry; Marelize Swart; Elizabeth B Medeiros; Todd C Skaar; Victoria M Pratt
Journal:  Genet Test Mol Biomarkers       Date:  2018-10-23

4.  Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in Serbian population.

Authors:  Ivana Joksic; Zeljko Mikovic; Dejan Filimonovic; Jelena Munjas; Orlic Natasa Karadzov; Amira Egic; Gordana Joksic
Journal:  J Med Biochem       Date:  2020-01-23       Impact factor: 3.402

5.  Compound heterozygous variants of MTHFR presenting as treatable leukodystrophy with reversible visuospatial deficits.

Authors:  Arkaprava Chakraborty; Adreesh Mukherjee; Sumanta Sarkar; Souvik Dubey; Goutam Gangopadhyay
Journal:  Acta Neurol Belg       Date:  2022-03-24       Impact factor: 2.396

6.  Predicting the combined effect of multiple genetic variants.

Authors:  Mingming Liu; Layne T Watson; Liqing Zhang
Journal:  Hum Genomics       Date:  2015-07-30       Impact factor: 4.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.